Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hepatitis C

Viral suppression restores life expectancy in hepatitis C-related cirrhosis

Study shows sustained virologic response in patients with hepatitis C and cirrhosis dramatically improves survival.

In patients with cirrhosis and hepatitis C virus (HCV) it has been hard to define the benefit of sustained virologic response (SVR) on patients’ survival because of selection bias and other confounding factors in studies. 

To overcome this, researchers studied 796 patients with HCV-related cirrhosis treated with interferon-based antiviral therapy and compared them with age and sex-matched people from the general population. Overall, 181 (22.7%) achieved SVR. 

Over a median follow-up of 9.6 years, 28 (15.5%) patients who achieved SVR died – a similar rate to the overall population. However, among patients without SVR (n=615), the standardised mortality rate was nearly four times greater than the general population. 

Reporting in the Journal of Hepatology (online, 5 April 2016)[1], the researchers say the results support the case for using non-interferon antiviral therapies to achieve SVR in more patients and sicker patients with HCV.

Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2016.20201169

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Micrograph of a liver with hepatitis C

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.